Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 3/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.44 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CASR | P41180 | 2/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27276871 | 0.98 | AOC3 (0.43) | AOC3MTNR1AMTNR1BALOX5PPARG | |
| SCHEMBL28943802 | 0.89 | PLAT (0.42) | ALOX5PPARGPPARA | |
| SCHEMBL11618534 | 0.87 | AOC3 (0.46) | AOC3MTNR1AMTNR1BALOX5PPARG | |
| SCHEMBL2744792 | 0.84 | POLB (0.37) | ALOX5PPARGPPARA | |
| SCHEMBL2179193 | 0.83 | AOC3 (0.49) | AOC3MTNR1AMTNR1BL3MBTL1CASR | |
| SCHEMBL6702192 | 0.82 | MTNR1A (0.46) | AOC3MTNR1AMTNR1BALOX5PPARG | |
| SCHEMBL6055156 | 0.82 | AOC3 (0.60) | AOC3MTNR1AMTNR1BALOX5L3MBTL1 | |
| SCHEMBL11619991 | 0.82 | AOC3 (0.45) | AOC3MTNR1AMTNR1BL3MBTL1CASR | |
| SCHEMBL14441698 | 0.82 | CASR (0.47) | AOC3MTNR1AMTNR1BL3MBTL1CASR | |
| SCHEMBL18937394 | 0.81 | AOC3 (0.44) | AOC3MTNR1AMTNR1BALOX5PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020243135-A1 | FUSED HETEROCYCLIC DERIVATIVES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-12-03 | — | — | WO | disclosed |
| EP-1740576-B1 | NOVEL PIPERIDINE SUBSTITUTED DIAMINOTHIAZOLES | HOFFMANN LA ROCHE (CH) | 2009-07-01 | — | — | EP | disclosed |
| US-7211576-B2 | Diaminothiazoles | HOFFMANN-LA ROCHE INC. (US) | 2007-05-01 | — | — | US | disclosed |
| EP-1740576-A1 | NOVEL PIPERIDINE SUBSTITUTED DIAMINOTHIAZOLES | F. Hoffman-la Roche AG (CH) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005103034-A1 | NOVEL PIPERIDINE SUBSTITUTED DIAMINOTHIAZOLES | F. HOFFMAN-LA ROCHE AG (CH) | 2005-11-03 | — | — | WO | disclosed |
| US-20050239843-A1 | Diaminothiazoles | DING QINGJIE | 2005-10-27 | — | — | US | disclosed |
| US-6071935-A | Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors | PFIZER INC. (US) | 2000-06-06 | — | — | US | disclosed |
| EP-0907649-A1 | DERIVATIVES OF 2-(2-OXO-ETHYLIDENE)-IMIDAZOLIDIN-4-ONE AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | PFIZER INC. (US) | 1999-04-14 | — | — | EP | disclosed |
| WO-1997049700-A1 | DERIVATIVES OF 2-(2-OXO-ETHYLIDENE)-IMIDAZOLIDIN-4-ONE AND THEIR USE AS FARNESYL PROTEIN TRANSFERASE INHIBITORS | PFIZER INC. (US) | 1997-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239843-A1 | Diaminothiazoles | CDK4, CDK2, CDK1 | AOC3 4422/4885MTNR1A 2443/4885MTNR1B 2434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.